Brokerages Set Roivant Sciences Ltd. (NASDAQ:ROIV) Price Target at $18.08

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $18.08.

A number of equities research analysts have issued reports on ROIV shares. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th.

Insider Buying and Selling

In other news, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the transaction, the chief operating officer now directly owns 732,294 shares in the company, valued at $8,260,276.32. The trade was a 12.01 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Rakhi Kumar sold 227,500 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,875,586 shares of company stock worth $21,491,661 over the last ninety days. Company insiders own 7.90% of the company’s stock.

Institutional Trading of Roivant Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its holdings in shares of Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after acquiring an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Roivant Sciences during the 4th quarter worth approximately $39,000. US Bancorp DE lifted its holdings in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after acquiring an additional 1,948 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after acquiring an additional 1,507 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Down 1.6 %

Shares of NASDAQ:ROIV opened at $10.79 on Wednesday. The company’s fifty day moving average is $10.78 and its two-hundred day moving average is $11.47. Roivant Sciences has a 12-month low of $9.93 and a 12-month high of $13.06. The company has a market cap of $7.70 billion, a P/E ratio of -71.93 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities research analysts anticipate that Roivant Sciences will post -0.92 earnings per share for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.